News

BridgeBio's Encaleret Shows Promise in Rare Calcium Disorder

BridgeBio's Encaleret Shows Promise in Rare Calcium Disorder

Introduction to BridgeBio's Encaleret

BridgeBio Pharma Inc. (NASDAQ: BBIO) has made significant strides in the treatment of autosomal dominant hypocalcemia type 1 (ADH1) with their investigational drug, encaleret. This drug aims to address a genetic disorder that leads to low blood calcium levels and insufficient parathyroid hormone (PTH) secretion. The latest topline results from the CALIBRATE Phase 3 study offer promising insights into encaleret's effectiveness compared to conventional therapies.

Understanding Autosomal Dominant Hypocalcemia

ADH1 is a rare condition characterized by persistently low serum calcium levels, which can lead to various health complications. Individuals affected by this disorder often struggle with symptoms that stem from calcium deficiency, emphasizing the need for effective treatment options. Encaleret works by inhibiting certain receptors involved in calcium regulation, aiming to restore normal calcium levels in the body.

Results from the CALIBRATE Study

The CALIBRATE study's primary endpoint measured the proportion of individuals receiving encaleret who reached optimal levels of both serum and urine calcium. Impressively, 76% of participants treated with encaleret achieved this goal, while only 4% managed to do so with conventional therapies. This stark contrast highlights the potential of encaleret in managing ADH1 effectively.

Secondary Assessments and Safety Profile

Beyond the primary outcomes, secondary analyses focused on assessing additional benefits such as albumin-corrected calcium levels and intact PTH metrics. Notably, no encaleret responders required any traditional treatment measures during the follow-up periods, further demonstrating the drug's efficacy. Participants generally tolerated encaleret well, with a significant majority opting to continue in the study's long-term extension.

Plans for Regulatory Submissions

Looking ahead, BridgeBio intends to submit its New Drug Application (NDA) to the FDA in the coming years, with a follow-up plan for a Marketing Authorization Application to the European Medicines Agency. Additionally, the company plans to initiate a registrational trial for encaleret in pediatric patients suffering from ADH1, with expectations to commence studies for adults with chronic hypoparathyroidism as well.

BBIO Stock Performance

As of the latest updates, shares of BridgeBio Pharma have seen an uptick of 4.72% to reach $67.54. This uptick arrives as the company prepares for significant clinical milestones that could affect its market position. The stock has recently achieved a new 52-week high, indicating growing investor confidence driven by encouraging study results.

The Broader Outlook on Calcium Disorders

The advancements represented by encaleret underscore the importance of innovation in the management of rare diseases. As the medical community continues to address the challenges presented by calcium disorders, therapies like encaleret provide hope to affected individuals and families. These developments not only exhibit the need for targeted treatments but also reflect the evolving landscape of pharmaceutical options available for rare conditions.

Frequently Asked Questions

What is encaleret?

Encaleret is an investigational drug being studied for its potential to treat autosomal dominant hypocalcemia type 1 by modulating calcium-sensing receptors.

What were the results of the CALIBRATE study?

The CALIBRATE study showed that 76% of participants achieved optimal serum calcium levels using encaleret compared to just 4% with standard therapies.

When does BridgeBio plan to submit regulatory applications?

BridgeBio plans to submit its New Drug Application to the FDA in the first half of 2026, followed by a Marketing Authorization Application to the European Medicines Agency.

How has BBIO stock performed recently?

BridgeBio Pharma's stock has risen by 4.72%, reaching $67.54, and has achieved a new 52-week high, reflecting positive reactions to its recent study results.

What are the future plans for encaleret?

In addition to submitting regulatory applications, BridgeBio aims to launch a trial for encaleret in pediatric ADH1 patients and commence a Phase 3 study for adults with chronic hypoparathyroidism in 2026.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 88

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 121

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 119

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 123

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 135

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 242

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 100

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 90

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading

Top 5 Most Recently Viewed Articles

Protecting Your Rights as a Match Group, Inc. Investor

Updated Category News Views 82

Understanding Your Legal Rights as a Match Group, Inc. Investor Investors in Match Group, Inc. have been notified about an important class action securities lawsuit initiated by Levi & Korsinsky, LLP. This legal action aims to safeguard the interests of investors who might have suffered financial losses due to alleged securities fraud. What is the Class Action Lawsuit...

Continue Reading
Experience Cutting-Edge Communication Solutions at MWC25

Updated Category News Views 449

Hytera Communications at MWC25 Hytera Communications, a leading provider of professional communications technologies and solutions, is excited to announce its participation in the upcoming Mobile World Congress 2025 (MWC25). This prestigious event will take place at the Fira Gran Via in Barcelona. Hytera is eager to showcase its innovative portfolio of mission-critical...

Continue Reading
Home Chef's New Partnership with Giada: What's the Scoop?

Updated Category News Views 241

Home Chef's Flavorful Collaboration This takes me back, ya know? Reminds me of when brands tried to jazz things up with culinary pros. Home Chef, that name's been buzzing around the meal kit world, right? They’ve teamed up with culinary superstar Giada De Laurentiis—an Emmy winner, no less—for an exclusive eight-week menu packed with Italian flair. Like, who...

Continue Reading
Angeles Equity Partners Welcomes Chetan Bhandari as Leader

Updated Category News Views 315

Angeles Equity Partners Enhances Leadership with New Appointment Angeles Equity Partners, a well-regarded private investment firm, announces the addition of Chetan Bhandari as the new Head of Capital Markets within the Angeles Operations Group. Bhandari enters this role equipped with over 30 years of rich experience in the financial sector. His expertise spans advising...

Continue Reading
Investors Alert: Join Ready Capital Corporation Class Action

Updated Category News Views 246

Understanding the Class Action Opportunity for Investors The landscape for investors can often seem daunting, particularly with securities fraud cases disrupting the financial market's integrity. One prominent case currently unfolding involves Ready Capital Corporation, traded under NYSE: RC. A class action lawsuit is underway, which gives affected investors a chance to...

Continue Reading